Zacks: Analysts Expect Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Will Announce Quarterly Sales of $22.68 Million

Equities research analysts expect that Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) will announce sales of $22.68 million for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Arrowhead Pharmaceuticals’ earnings. The lowest sales estimate is $17.80 million and the highest is $36.00 million. Arrowhead Pharmaceuticals reported sales of $48.15 million during the same quarter last year, which indicates a negative year over year growth rate of 52.9%. The company is scheduled to report its next earnings report on Wednesday, May 13th.

On average, analysts expect that Arrowhead Pharmaceuticals will report full-year sales of $109.11 million for the current year, with estimates ranging from $50.00 million to $257.80 million. For the next year, analysts forecast that the firm will report sales of $128.73 million, with estimates ranging from $40.00 million to $231.00 million. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Wednesday, February 5th. The biotechnology company reported ($0.03) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.04 by ($0.07). Arrowhead Pharmaceuticals had a return on equity of 18.21% and a net margin of 32.56%. The company had revenue of $29.46 million during the quarter, compared to the consensus estimate of $36.63 million.

ARWR has been the subject of several research reports. Piper Jaffray Companies upped their price objective on shares of Arrowhead Pharmaceuticals from $72.00 to $80.00 and gave the stock an “overweight” rating in a report on Monday, December 9th. Robert W. Baird upgraded shares of Arrowhead Pharmaceuticals from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $39.00 to $70.00 in a report on Monday, November 25th. Jefferies Financial Group upped their price objective on shares of Arrowhead Pharmaceuticals from $77.00 to $80.00 in a report on Friday, February 7th. Cantor Fitzgerald upped their price objective on shares of Arrowhead Pharmaceuticals from $50.00 to $55.00 and gave the stock a “neutral” rating in a report on Thursday, February 6th. Finally, Oppenheimer initiated coverage on shares of Arrowhead Pharmaceuticals in a report on Thursday, December 12th. They issued a “hold” rating for the company. Three analysts have rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $64.13.

In other news, CFO Kenneth Allen Myszkowski sold 40,313 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $49.44, for a total value of $1,993,074.72. Following the sale, the chief financial officer now directly owns 424,536 shares of the company’s stock, valued at approximately $20,989,059.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Christopher Richard Anzalone sold 100,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $67.50, for a total transaction of $6,750,000.00. Following the completion of the sale, the chief executive officer now directly owns 2,048,684 shares in the company, valued at $138,286,170. The disclosure for this sale can be found here. Insiders sold a total of 248,518 shares of company stock worth $15,591,357 over the last ninety days. Insiders own 4.00% of the company’s stock.

A number of hedge funds have recently made changes to their positions in ARWR. BlackRock Inc. grew its position in Arrowhead Pharmaceuticals by 94.5% during the 2nd quarter. BlackRock Inc. now owns 14,841,966 shares of the biotechnology company’s stock valued at $393,313,000 after purchasing an additional 7,210,892 shares during the last quarter. Eagle Asset Management Inc. purchased a new stake in Arrowhead Pharmaceuticals during the 4th quarter valued at about $44,658,000. FMR LLC grew its position in Arrowhead Pharmaceuticals by 38.9% during the 4th quarter. FMR LLC now owns 1,881,408 shares of the biotechnology company’s stock valued at $119,338,000 after purchasing an additional 526,552 shares during the last quarter. Credit Suisse AG grew its position in Arrowhead Pharmaceuticals by 268.4% during the 4th quarter. Credit Suisse AG now owns 381,224 shares of the biotechnology company’s stock valued at $24,182,000 after purchasing an additional 277,732 shares during the last quarter. Finally, American International Group Inc. grew its position in Arrowhead Pharmaceuticals by 260.2% during the 4th quarter. American International Group Inc. now owns 250,099 shares of the biotechnology company’s stock valued at $15,864,000 after purchasing an additional 180,656 shares during the last quarter. 66.53% of the stock is currently owned by institutional investors.

NASDAQ ARWR traded down $1.25 during trading on Friday, hitting $38.49. The company had a trading volume of 1,057,079 shares, compared to its average volume of 1,457,754. The company has a current ratio of 6.89, a quick ratio of 6.89 and a debt-to-equity ratio of 0.03. Arrowhead Pharmaceuticals has a one year low of $17.27 and a one year high of $73.72. The company has a market cap of $4.04 billion, a price-to-earnings ratio of 72.62 and a beta of 1.95. The company’s fifty day moving average is $48.22 and its 200-day moving average is $44.22.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.

See Also: Green Investing

Get a free copy of the Zacks research report on Arrowhead Pharmaceuticals (ARWR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.